ストックスクリーナーアプリを入手
108.24
1.11%
1.19
前日終値:
$107.05
開ける：
$106.94
24時間の取引高:
601.34K
Relative Volume:
0.50
時価総額：
$6.84B
収益：
$3.99B
当期純損益:
$463.16M
株価収益率:
15.25
EPS:
7.1
ネットキャッシュフロー:
$1.10B
1週間 パフォーマンス:
-2.05%
1か月 パフォーマンス:
-0.68%
6か月 パフォーマンス:
-11.09%
1年 パフォーマンス:
-3.94%
1日の値動き範囲:
$106.56
$109.43
1週間の範囲:
$106.56
$111.45
52週間の値動き範囲:
$95.49
$148.06
Jazz Pharmaceuticals Plc Stock (JAZZ) Company Profile
名前
Jazz Pharmaceuticals Plc
セクター
電話
353-1-634-7800
住所
FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN
JAZZ を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
JAZZ
Jazz Pharmaceuticals Plc
|
108.24 | 6.84B | 3.99B | 463.16M | 1.10B | 7.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
448.40 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
513.58 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
312.32 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
537.92 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
252.78 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Jazz Pharmaceuticals Plc Stock (JAZZ) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-07 | アップグレード | UBS | Neutral → Buy |
| 2025-02-26 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2025-02-13 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2024-12-12 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2024-06-05 | 開始されました | Goldman | Buy |
| 2024-01-03 | 開始されました | Robert W. Baird | Outperform |
| 2023-11-27 | ダウングレード | UBS | Buy → Neutral |
| 2023-09-29 | 開始されました | Raymond James | Mkt Perform |
| 2023-06-12 | 再開されました | Wells Fargo | Equal Weight |
| 2022-12-09 | アップグレード | Goldman | Neutral → Buy |
| 2022-06-14 | 開始されました | UBS | Buy |
| 2022-04-06 | ダウングレード | Goldman | Buy → Neutral |
| 2021-11-19 | 再開されました | Goldman | Buy |
| 2021-10-07 | 再開されました | Jefferies | Buy |
| 2021-10-05 | 開始されました | Citigroup | Buy |
| 2021-09-23 | 開始されました | Needham | Buy |
| 2021-05-19 | 再開されました | JP Morgan | Overweight |
| 2021-04-07 | 再開されました | RBC Capital Mkts | Outperform |
| 2021-02-05 | 繰り返されました | H.C. Wainwright | Buy |
| 2021-02-03 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2021-01-29 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-16 | 開始されました | UBS | Buy |
| 2020-11-03 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-10-09 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-09-14 | ダウングレード | Goldman | Neutral → Sell |
| 2020-09-14 | 再開されました | JP Morgan | Overweight |
| 2020-08-06 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-07-28 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2020-07-23 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2020-04-06 | 開始されました | Jefferies | Buy |
| 2020-03-12 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2020-01-08 | 開始されました | Goldman | Neutral |
| 2019-08-21 | ダウングレード | Piper Jaffray | Overweight → Neutral |
| 2019-06-11 | 開始されました | Barclays | Overweight |
| 2019-03-20 | 開始されました | SunTrust | Buy |
| 2018-12-14 | 開始されました | Wolfe Research | Peer Perform |
| 2018-11-08 | 繰り返されました | B. Riley FBR | Buy |
| 2018-08-08 | 繰り返されました | Stifel | Buy |
| 2018-07-11 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2018-03-23 | 繰り返されました | H.C. Wainwright | Neutral |
| 2018-03-19 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
すべてを表示
Jazz Pharmaceuticals Plc (JAZZ) 最新ニュース
FDA Approvals and Clinical Trials Impacting Narcolepsy - openPR.com
Pharma 50: The top pharma companies in the world for 2025 - drugdiscoverytrends.com
Autistic Disorder Pipeline 2025: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | Jazz Pharma, Axial Therapeutics, Eli Lilly and Company, Scioto Biosciences - Barchart.com
Jazz Pharmaceuticals Releases Unexpected Phase 4 Results Highlighting Xywav® - Insider Monkey
Jazz Pharmaceuticals Releases Unexpected Phase 4 Results Highlighting Xywav®. - Yahoo Finance
13 Biotech Stocks with Huge Upside Potential - Insider Monkey
Jazz Pharmaceuticals (JAZZ) Stock Ratings Reiterated by Needham - GuruFocus
Jazz Pharmaceuticals at Goldman Sachs Conference: Strategic Growth and Challenges - Investing.com Nigeria
Transcript : Jazz Pharmaceuticals plc Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 10 - MarketScreener
Transcript : Jazz Pharmaceuticals plcSpecial Call - MarketScreener
Jazz Pharmaceuticals Says Zepzelca-Tecentriq Combination Gets FDA Priority Review for Lung Cancer Treatment - marketscreener.com
FDA Fast-Tracks Jazz Pharmaceuticals' Lung Cancer Drug Application - GuruFocus
Jazz Pharma stock gains on FDA review for lung cancer therapy - Seeking Alpha
Jazz Pharmaceuticals (JAZZ) Awaits FDA Decision on Lung Cancer Treatment | JAZZ Stock News - GuruFocus
FDA Fast-Tracks Revolutionary Lung Cancer Drug That Cuts Disease Progression Risk by 46% - Stock Titan
Jazz Pharmaceuticals Says Narcolepsy Drug Meets Primary Endpoint in Phase 4 Trial - marketscreener.com
Parallel Advisors LLC Acquires 119 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - Defense World
Jazz Pharmaceuticals (JAZZ) Reveals New Findings on Xywav at SLE - GuruFocus
Jazz Pharmaceuticals Presents Late-Breaking Phase 4 Data Showcas - GuruFocus
Jazz Pharmaceuticals Presents Late-Breaking Phase 4 Data Showcasing Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Outcomes in Narcolepsy at SLEEP 2025 - PR Newswire
Jazz Pharmaceuticals' Xywav Achieves 4.1 mmHg Blood Pressure Reduction in Groundbreaking Phase 4 Trial - Stock Titan
Transcript : Jazz Pharmaceuticals plc Presents at Jefferies Global Healthcare Conference 2025, Jun-05-2025 09 - MarketScreener
Jazz Pharmaceuticals misses estimates, slashes guidance on litigation costs By Investing.com - Investing.com Nigeria
Why Is Jazz (JAZZ) Up 7.9% Since Last Earnings Report? - Yahoo Finance
May 2026 Options Now Available For Jazz Pharmaceuticals - Nasdaq
Needham Says Promising Data Underscore Growth Potential for Jazz Pharma (JAZZ) - MSN
Insider Sell: Bruce Cozadd Sells Shares of Jazz Pharmaceuticals PLC - GuruFocus
Jazz Pharmaceuticals plc (JAZZ)’s Zepzelca Combo Boosts Survival in ES-SCLC - MSN
Psychedelic Drugs Market 2025 | Growth Trends, Mental Health - openPR.com
Jazz Pharmaceuticals (NASDAQ:JAZZ) Given “Buy” Rating at Needham & Company LLC - Defense World
Jazz Pharma's Zepzelca Combo Shows Survival Edge In Lung Cancer StudyJazz Pharmaceuticals (NASDAQ:JAZZ) - Benzinga
UBS maintains buy rating on Jazz Pharmaceuticals stock after positive trial data - Investing.com Nigeria
Jazz Pharmaceuticals succeeds in late-stage study of lung cancer treatment - MSN
The Analyst Verdict: Jazz Pharmaceuticals In The Eyes Of 11 Experts - Benzinga
Jazz Pharmaceuticals (JAZZ) Maintains Buy Rating with $202 Price Target | JAZZ Stock News - GuruFocus
Jazz Pharmaceuticals reports promising Phase 2 trial results for Ziihera By Investing.com - Investing.com South Africa
Jazz Pharmaceuticals (JAZZ) Reports Positive Results for Zepzelc - GuruFocus
Jazz Pharmaceuticals (JAZZ) Reveals Promising Phase 3 Trial Resu - GuruFocus
Jazz Pharmaceuticals Announces Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination - marketscreener.com
Jazz Pharmaceuticals (JAZZ) Reveals Promising Phase 3 Trial Results for Zepzelca | JAZZ Stock News - GuruFocus
Zepzelca combo extends survival in lung cancer study - Investing.com
Phase 3 Trial: Zepzelca Combo Cuts Lung Cancer Progression Risk by 46% | JAZZ Stock News - Stock Titan
Jazz Pharmaceuticals (JAZZ) Reports Promising Long-term Data for Ziihera | JAZZ Stock News - GuruFocus
Jazz Pharmaceuticals Says Ziihera Achieves Over 3 Years Median Overall Survival in Gastroesophageal Cancer - marketscreener.com
Jazz Pharmaceuticals reports promising Phase 2 trial results for Ziihera - Investing.com
Jazz Pharmaceuticals (JAZZ) Reports Clinically Meaningful Long-Term Median Overall Survival Data for Ziihera in mGEA - StreetInsider
Jazz Pharmaceuticals Reports Clinically Meaningful Long-Term Median Overall Survival Data for Ziihera® (zanidatamab-hrii) in First-Line HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ASCO 2025 - PR Newswire
Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer - GlobeNewswire Inc.
Jazz Pharmaceuticals to Present Expansive Research Demonstrating Comprehensive Treatment Benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) in Sleep Conditions and Associated Como - GuruFocus
Jazz Pharmaceuticals Reveals 19 New Xywav Studies for Sleep Disorders at SLEEP 2025 | JAZZ Stock News - Stock Titan
Jazz Pharmaceuticals to Present Expansive Research Demonstrating Comprehensive Treatment Benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) in Sleep Conditions and Associated Comorbidities at SLEEP 2025 - PR Newswire
Jazz Pharmaceuticals Plc (JAZZ) 財務データ
収益
当期純利益
現金流量
EPS
Jazz Pharmaceuticals Plc (JAZZ) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| COZADD BRUCE C | Chairman & CEO |
Jun 02 '25 |
Sale |
107.90 |
500 |
53,950 |
438,473 |
2.13%
1.01%
大文字化:
|
ボリューム (24 時間):